Nuvectis Pharma Q1 2026 net loss $6.1M; cash $25.1M; NXP900 Phase 1b data expected summer

Nuvectis Pharma, Inc.

2026-Q1 EPS reported -$0.26

Cash and equivalents $25.1M as of March 31, 2026, down from $31.6M at Dec 31, 2025.
Net loss $6.1M for Q1 2026 vs $5.3M in Q1 2025, increase driven by R&D and G&A costs.
R&D expenses $4.1M, up $0.4M YoY; G&A $2.2M, up $0.3M YoY.
NXP900 Phase 1b clinical program enrolling patients in US; monotherapy and combination arms ongoing.
Preliminary Phase 1b data readout for NXP900 expected in summer 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Nuvectis Pharma, Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 5, 2026, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the first quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Nuvectis Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-26-055264

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.